Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 925-931

  Parke III, Wilkin D ^a   Sisk, Robert A ^a   Houston, Samuel K ^a   Murray, Timothy G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cataract; Glaucoma; Inflammation

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CATARACT; CENTRAL SEROUS RETINOPATHY; CLINICAL EVALUATION; CLOSED ANGLE GLAUCOMA; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; EXUDATIVE RETINITIS; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR GLAUCOMA; OUTCOME ASSESSMENT; PHACOEMULSIFICATION; POLYPOIDAL CHOROIDAL VASCULOPATHY; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRESSURE MEASUREMENT; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA EDEMA; RETINA MACULA HOLE; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION; VITRECTOMY;

EID: 84863427275     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S32934     Document Type: Article

References (21)

1. Chuang LH, Yeung L, Wang NK, Chen HS, Ku WC, Lai CC. Secondary ocular hypertension after intravitreal injection with 2mg or 4mg of triamcinolone in retinal vein occlusion. J Ocul Pharmacol Ther. 2010;26(4):325-328.
2. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4mg of triamcinolone acetonide: incidence and risk factors. Retina. 2008;28(4):573-580.
3. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29(1):2-6.
4. Wingate RJB, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust NZJ Ophthalmol. 1999;27(6):431-432.
5. Chin H, Park T, Moon Y, Oh J. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25(5):556-560.
6. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982;93(4):415-417.
7. Chang S. LXII Edward Jackson lecture: open angle glaucoma after vitrectomy. Am J Ophthalmol. 2006;141(6):1033-1043.
8. Koreen L, Yoshida N, Escariao P, etal. Incidence of, risk factors for, and combined mechanism of late-onset open-angle glaucoma after vitrectomy. Retina. 2011;32(1):160-167.
9. Blankenship GW, Flynn HW Jr, Kokame GT. Posterior chamber intraocular lens insertion during pars plana lensectomy and vitrectomy for complications of proliferative diabetic retinopathy. Am J Ophthalmol. 1989;108(1):1-5.
10. Jun Z, Pavlovic S, Jacobi KW. Results of combined vitreoretinal surgery and phacoemulsification with intraocular lens implantation. Clin Experiment Ophthalmol. 2001;29(5):307-311.
11. Soheilian M, Mirdehqhan SA, Peyman GA. Sutureless combined 25-gauge vitrectomy, phacoemulsification, and posterior chamber intraocular lens implantation for management of uveitic cataract associated with posterior segment disease. Retina. 2008;28(7):941-946.
12. Lee DY, Jeong HS, Sohn HJ, Nam DH. Combined 23-gauge sutureless vitrectomy and clear corneal phacoemulsification in patients with proliferative diabetic retinopathy. Retina. 2011;31(9):1753-1758.
13. Hikichi T, Kosaka S, Takami K, etal. 23-and 20-gauge vitrectomy with air tamponade with combined phacoemulsification for idiopathic macular hole: a single-surgeon study. Am J Ophthalmol. 2011;152(1):114-121.
14. Enaida H, Hata Y, Ueno A, etal. Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina. 2003;23(6): 764-770.
15. Bhisitkul RB, Winn BJ, Lee OT, etal. Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage. Invest Ophthalmol Vis Sci. 2008;49(9):4071-4077.
16. Ebrahem Q, Minamoto A, Hoppe G, Anand-Apte B, Sears JE. Triamcinolone acetonide inhibits IL-6 and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci. 2006;47(11):4935-4941.
17. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. Arch Ophthalmol. 2009;127(9):1101-1114.
18. Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004;138(6):1046-1048.
19. Konstantinidis L, Gerguiga M, Beknazar E, Wolfensberger TJ. Anatomic and functional outcome after 23-gauge vitrectomy, peeling, and intravitreal triamcinolone for idiopathic macular epiretinal membrane. Retina. 2009;29(8):1119-1127.
20. Moshfeghi AA, Nugent AK, Nomoto H, Sanislo SR, Kitchens JW, Moshfeghi DM. Triamcinolone acetonide preparations: impact of crystal size on in vitro behavior. Retina. 2009;29(5):689-698.
21. Spitzer MS, Mlynczak T, Schultheiss M, etal. Preservative-free triamcinolone acetonide injectable suspension versus "traditional" triamcinolone preparations: impact of aggregate size on retinal biocompatibility. Retina. 2011;31(10):2050-2057.